• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Sequel twiist AID System to Integrate with Senseonics Eversense 365 One-Year CGM

by Jasmine Pennic 04/30/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement. 

– The collaboration will integrate Sequel’s twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, with Senseonics’ Eversense® 365 CGM system.

This partnership marks a notable advancement in diabetes management, as the twiist™ AID System is set to become the first automated insulin delivery system compatible with the Senseonics Eversense 365. The Eversense 365 stands out as the world’s only CGM system featuring a sensor designed to last for a full year, offering unprecedented longevity for users. The integration aims to provide people living with type 1 diabetes a new level of flexibility and personalization in managing their condition.

This agreement expands the choices available to users of the twiist™ system. Once integrated, individuals with type 1 diabetes using twiist will have the flexibility to select between two compatible CGM partners: the Senseonics Eversense 365 or Abbott’s FreeStyle Libre 3 Plus sensor, allowing them to choose the option that best suits their individual needs.

FDA Clearance

The path for this integration was paved in September 2024 when the Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system, specifically allowing its use within AID systems. Driven by a shared commitment to simplifying diabetes management, Senseonics and Sequel have already commenced the integration work.

The twiist™ AID System itself, cleared for use in individuals aged six and older with type 1 diabetes, features unique technology that directly measures the volume of insulin delivered with each micro-dose. Its algorithm, based on the community-driven Tidepool Loop, automatically adjusts basal insulin delivery using real-time CGM data and predictive glucose levels. The twiist system is expected to be commercially available in the second quarter of 2025.

Availability

The integrated Eversense 365 and twiist™ system is anticipated to be available to users in the third quarter of 2025, marking a significant milestone in offering more personalized and convenient diabetes management solutions.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Continuous Glucose Monitoring (CGM), Diabetes Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |